Assessment of the Treatment for Alcohol Withdrawal Syndrome With and Without Dexmedetomidine: A Retrospective Cohort Study

Authors

  • Apurva Ashok
  • Rohit Sharma
  • Shoaib Ahmed
  • Evan M. Calvo
  • Justina Warnick
  • Dipen Zalavadia
  • Shiva Naidoo
  • Tristan Nguyen-Luu
  • Greg Simonetti
  • Sara Humayun
  • Roop Sunil Parlapalli
  • Connor Dougherty
  • Wasique Mirza
  • Ben Illigens

DOI:

https://doi.org/10.14740/jocmr6361

Keywords:

Alcohol withdrawal syndrome, Alcohol withdrawal, Dexmedetomidine, Benzodiazepine

Abstract

Background: Alcohol withdrawal syndrome (AWS) carries a high risk of morbidity and mortality that often requires critical care admission and monitoring. Dexmedetomidine is a known sedative that can help with patient symptoms and potentially reduce Clinical Institute Withdrawal Assessment of Alcohol Scale Revised (CIWA-Ar) scores. This study looks at two groups - the use of dexmedetomidine versus non-dexmedetomidine - in the management of AWS patients to assess the length of intensive care unit (ICU) stay, length of stay (LOS) in hospital, mortality and readmission rate.

Methods: This retrospective cohort study was conducted at Geisinger Health System, a tertiary care, academic health care system, between January 2016 and December 2022. This study did not require ethics approval according to the Institutional Review Board (IRB). The patients assessed included those aged 18 years or older with a documented CIWA-Ar score requiring admission to the ICU or ICU step-down unit. Exclusion criteria included ICU admission for alternative indications, a prior history of seizure disorder, or patients who left against medical advice.

Results: A total of 994 patients were identified to have met the inclusion criteria; 371 patients were in the non-dexmedetomidine group and 623 in the dexmedetomidine group. Primary outcomes assessed were hospital LOS (5.0 (3.0 - 9.0) vs. 10 (6.0 - 16.0), P < 0.0001) and days in the ICU (1.9 (1.0 - 3.4) vs. 4.9 (2.9 - 9.0), P < 0.0001), respectively. Secondary outcomes assessed were lorazepam equivalent usage, and readmission within 30, 60 and 90 days, which were not statistically significant when accounting for ICU LOS.

Conclusions: Among patients treated for AWS, dexmedetomidine use appeared to be associated with longer hospital and ICU stays, while benzodiazepine requirements remained unchanged. These associations may reflect differences in illness severity, emphasizing the need for future prospective evaluation.

Author Biographies

  • Apurva Ashok, Mass General Brigham Salem Hospital

    Mass General Brigham Salem Hospital, Department of Medicine, MA, USA

  • Rohit Sharma, Mass General Brigham Salem Hospital

    Attending, Medicine Department

  • Shoaib Ahmed, Punjab Medical College

    Resident, Medicine Department

  • Evan M. Calvo, University of Pennsylvania

    Resident, Psychiatry Department

  • Justina Warnick, University of Connecticut School of Medicine

    Resident, Psychiatry Department

  • Dipen Zalavadia, Wright Center for Graduate Medical Education

    Resident, Cardiology Department 

  • Shiva Naidoo, SSM Health, St Louis University

    Resident, Medicine Department

  • Tristan Nguyen-Luu, Geisinger Health System

    Fellow, Department of Pulmonary, Critical Care and Sleep Medicine 

  • Greg Simonetti, Geisinger Health System

    Fellow, Department of Pulmonary, Critical Care and Sleep Medicine

  • Sara Humayun, Geisinger Health System

    Resident, Medicine Department

  • Connor Dougherty, Geisinger Health System

    Resident, Medicine Department

  • Wasique Mirza, Geisinger Health System

    Professor, Medicine Department

  • Ben Illigens, University Hospital Carl Gustav Carus, Technische Universität Dresden

    Professor, Neurology Department 

Downloads

Published

2025-11-26

Issue

Section

Original Article

How to Cite

1.
Ashok A, Sharma R, Ahmed S, et al. Assessment of the Treatment for Alcohol Withdrawal Syndrome With and Without Dexmedetomidine: A Retrospective Cohort Study. J Clin Med Res. 2025;17(11):601-607. doi:10.14740/jocmr6361